Section of Surgical Oncology Research, Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
J Immunother Cancer. 2018 Jan 8;6(1):3. doi: 10.1186/s40425-017-0312-8.
As infections and cancer are two of the most common maladies affecting human beings, a concerted effort is needed to better understand their potential interactions and to further explore their use in microbial-based cancer treatments. Studies focusing on the interaction between pathogens and cancer began over 4000 years ago, but therapeutic application of pathogens has often been bypassed as other cancer therapies have gained wider interest. To many, the field of microbial-based cancer treatment may feel antiquated and already sufficiently explored. However, closer examination reveals that our current knowledge is but a series of dim reflections amongst many yet-unexplored shadows. Particularly, with our increased understanding of pathogen entry, replication, and senescence, coupled with our quickly increasing knowledge regarding cancer initiation, growth, and metastasis, and capped by our realization of the complexity and plasticity of the immune response, we are just now beginning to realize the vastness of the undiscovered area encompassing this field. At the same time, we are now uniquely poised with gained knowledge and discovered tools to join together across disciplines, uncover new positive and negative interactions between pathogens and cancer, and make important progress toward saving cancer patient lives.
由于感染和癌症是影响人类的两种最常见疾病,因此需要共同努力,以更好地了解它们之间的潜在相互作用,并进一步探索它们在基于微生物的癌症治疗中的应用。关注病原体与癌症之间相互作用的研究已经开展了 4000 多年,但由于其他癌症疗法引起了更广泛的兴趣,病原体的治疗应用往往被忽略。对许多人来说,基于微生物的癌症治疗领域可能感觉陈旧,并且已经得到了充分的探索。然而,仔细研究后发现,我们目前的知识只是许多尚未探索的阴影中的一系列暗淡反映。特别是,随着我们对病原体进入、复制和衰老的理解不断加深,以及我们对癌症发生、生长和转移的知识迅速增加,再加上我们对免疫反应的复杂性和可塑性的认识,我们才刚刚开始意识到这个领域中未被发现的广阔领域。与此同时,我们现在凭借获得的知识和发现的工具,能够跨学科合作,揭示病原体和癌症之间新的正、负相互作用,并在拯救癌症患者生命方面取得重要进展。